We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Benchtop Diagnostic Platform Delivers Rapid Multi-Gene Test Results

By LabMedica International staff writers
Posted on 27 Nov 2023

In today’s rapidly advancing healthcare sector, the implementation of multi-gene testing is increasingly crucial. More...

This method efficiently uses limited tissue samples and significantly speeds up the time to get critical results. Now, a benchtop diagnostic platform for fully integrated analysis of molecular biomarker signatures with a 4-hour automated workflow allows hospitals and pathology labs to bring this advanced technology in-house, leading to quicker results and enhanced coordination in patient care.

BIOTYPE GmbH (Dresden, Germany) has significantly upgraded its MODAPLEX platform, making it easier for research and clinical labs to conduct sophisticated molecular analyses swiftly and automatically. The MODAPLEX system stands out for its ability to simultaneously detect and assess crucial biomarkers using a simple process. With an efficient workflow that takes less than four hours, the platform provides pathologists and clinicians with rapid and precise results. It enables the simultaneous measurement of key RNA and DNA biomarkers from a single sample, facilitating prompt initiation of optimal therapy and contributing to healthcare system efficiency.

BIOTYPE is now introducing an enhanced version of its hardware platform, featuring simplified software for automated analysis of cancer-related RNA and DNA biomarkers. The open-system nature of the MODAPLEX platform allows third parties, including molecular testing system developers and pharmaceutical companies, to create and distribute their own assays. This strategy broadens the range of available tests and makes the MODAPLEX platform more appealing to users who prefer sourcing test kits from various providers.

"The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms," said Dr Norman Gerstner, CEO of BIOTYPE GmbH. "Last year, we repositioned the company in the rapidly growing precision medicine market. In addition to molecular tests for highly specialized diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments. In addition, MODAPLEX is making an important contribution to meeting the growing demand for sophisticated technologies for multi-gene testing. MODAPLEX maximizes the use of existing tissue samples and reduces critical turnaround times."

Related Links:
BIOTYPE GmbH


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Sample Transportation System
Tempus1800 Necto
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.